Actylis – The Partner of Choice

Activities: Manufacturing Ingredients Research & Development

Trending Articles

  1. Grifols secures first EU approval for fibrinogen concentrate Prufibry in Germany Germany has granted the first marketing authorisation for Grifols’ fibrinogen concentrate Prufibry, approved for treating congenital and acquired fibrinogen deficiency
  2. Nanoform granted European Commercial cGMP Manufacturing Licence for APIs The Finnish company is now authorised to manufacture nanoformed APIs for the European market and for countries in the Middle East and North Africa, Asia and the Americas, where...
  3. TrakCel launches CGT Gateway to streamline cell and gene therapy access for healthcare providers The gateway will be a single sign-on platform designed to reduce portal fatigue and simplify how healthcare professionals manage cell and gene therapy products, supporting...
  4. Scottish immunology CRO RoukenBio celebrates 10 years of growth Formerly known as Antibody Analytics, the contract research organisation has grown from three employees to over 100 and enjoyed successes such as the launch of its first...
  5. DBV Technologies announces last patient visit completed in Phase III peanut allergy trial in children The Phase III VITESSE clinical trial of the VIASKIN Peanut patch in peanut allergic children aged 4-7 years remains on track for topline data in Q4 of this year

Related Content

Manufacturing

Actylis expands into VMS & Pharma with the acquisition of Pharm-Rx

The acquisition strengthens Actylis’ presence in the VMS and OTC markets
Manufacturing

Actylis appoints Scott Thomson as CEO

Scott will endeavour to globally expand the company's integrated manufacturing and sourcing strategy
Distribution

Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride

The two companies aim to expand the distribution of benzalkonium chloride within Europe
Manufacturing

Actylis adds a WFI production system in Canada

The manufacturer of raw materials has launched a Water for Injection (WFI) and additional ISO Class 7 manufacturing in Montreal, Canada
Manufacturing

Actylis opens 30,000 sqft cGMP API facility

The Eugene facility is the latest GMP manufacturing facility that Actylis has commissioned, along with the other GMP sites in Montreal, Limerick and Ahmedabad
Manufacturing

Actylis invests $450k in Manchester facility, UK

The modernisation work was completed during the summer of 2022
Manufacturing

The debut of Actylis signals the creation of a specialty ingredients manufacturing and sourcing powerhouse

The unique hybrid model provides unparalleled flexibility for individualised, customer-centric ingredient solutions along with exceptional supply chain dependability
Subscribe now